Cumberland Pharmaceuticals (NASDAQ:CPIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a report published on Sunday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Stock Performance

Shares of NASDAQ CPIX traded up $0.01 during trading on Friday, reaching $1.20. The company had a trading volume of 26,501 shares, compared to its average volume of 16,355. The company’s fifty day moving average price is $1.25 and its 200-day moving average price is $1.40. Cumberland Pharmaceuticals has a 12 month low of $1.07 and a 12 month high of $2.36. The company has a current ratio of 1.44, a quick ratio of 1.26 and a debt-to-equity ratio of 0.62.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.